2021
-
First Comprehensive Genomic Profiling Assay Approved for Use with Brigatinib, ALK-positive NSCLC
July 1, 2021—The U.S. Food and Drug Administration (FDA) has approved FoundationOne CDx for use as a companion diagnostic for brigatinib, which the FDA had previously approved for treatment of […]
-
High-Dose Once-Daily Thoracic Radiotherapy Did Not Improve OS in Limited Stage SCLC
High-dose 70 Gy once-daily thoracic radiotherapy did not significantly improve OS compared with the current standard of 45 Gy twice-daily radiotherapy in patients with limited-stage SCLC, according to results of […]
-
Single Institution’s Experience: SABR Shows Outstanding OS vs. VATS in Patients with Early-Stage NSCLC
Treatment of operable, stage-I NSCLC with stereotactic ablative radiotherapy (SABR) was noninferior to video-assisted thoracic surgery (VATS) with mediastinal lymph node dissection (L-MLND). Joseph Y. Chang, MD, of The University […]
-
Awareness-raising Bike Ride in The Netherlands Connected Hospitals, Patients
Patients and supporters cycled nearly 1,150 kilometers through The Netherlands on May 21, 2021 in a “White Ribbon Tour” to raise awareness for lung cancer. The grassroots event was organized […]
-
Understanding and Targeting SCLC
Lung cancer is the leading cause of cancer mortality worldwide, with an estimated 2.1 million new cases and 1.8 million deaths in 2018—more than colon, breast, and prostate cancers combined.1 […]
-
KRAS: Old Target, New Hope
As more data emerge and more investigational drugs are studied, the “undruggable” target is coming into focus.
-
Prophylactic Radiotherapy: A Case for Patients at High Risk of Brain Metastases
Prophylactic radiotherapy for the prevention of brain metastases (Table 1) has not been considered a standard practice outside of limited stage SCLC, particularly amid the surge and approval of novel […]
-
IMpower010: Adjuvant Atezolizumab Improved DFS in PD-L1 Expressing Stage II-IIIA NSCLC
Adjuvant atezolizumab significantly improved disease-free survival (DFS) compared with best supportive care after chemotherapy in patients with resected stage II-IIIA NSCLC, according to the results of the IMpower010 study presented […]
-
Selpercatinib Approved in Canada for Metastatic NSCLC with RET Fusions
June 15, 2021—Canada’s medical regulatory agency approved the use of selpercatinib monotherapy for treatment of patients with metastatic RET fusion–positive NSCLC. Health Canada based its conditional approval on the LIBRETTO-001 […]
-
Molecular Resistance Mechanisms to EGFR, ALK, and ROS1 TKIs
The identification of activating EGFR mutations and ALK and ROS1 rearrangements has ushered in an era of precision medicine for advanced NSCLC characterized by swift advances and adaptive drug development. […]
View ILCN Archives
Provider Resources